Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

CRANFORD, N.J., Aug. 10, 2023 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has reached an…